Cargando…

Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis

OBJECTIVES: The spectrum of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) represents highly inflammatory rheumatic diseases. Patients mostly report severe physical impairment. Possible consequences for mental health have been scarcely studied. The aim of this study was to investigate p...

Descripción completa

Detalles Bibliográficos
Autores principales: Froehlich, Matthias, Zahner, Antonia, Schmalzing, Marc, Gernert, Michael, Strunz, Patrick-Pascal, Hueper, Sebastian, Portegys, Jan, Schwaneck, Eva Christina, Gadeholt, Ottar, Kübler, Andrea, Hewig, Johannes, Ziebell, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262919/
https://www.ncbi.nlm.nih.gov/pubmed/37324155
http://dx.doi.org/10.3389/fmed.2023.1146815
_version_ 1785058131158499328
author Froehlich, Matthias
Zahner, Antonia
Schmalzing, Marc
Gernert, Michael
Strunz, Patrick-Pascal
Hueper, Sebastian
Portegys, Jan
Schwaneck, Eva Christina
Gadeholt, Ottar
Kübler, Andrea
Hewig, Johannes
Ziebell, Philipp
author_facet Froehlich, Matthias
Zahner, Antonia
Schmalzing, Marc
Gernert, Michael
Strunz, Patrick-Pascal
Hueper, Sebastian
Portegys, Jan
Schwaneck, Eva Christina
Gadeholt, Ottar
Kübler, Andrea
Hewig, Johannes
Ziebell, Philipp
author_sort Froehlich, Matthias
collection PubMed
description OBJECTIVES: The spectrum of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) represents highly inflammatory rheumatic diseases. Patients mostly report severe physical impairment. Possible consequences for mental health have been scarcely studied. The aim of this study was to investigate psychological well-being in the context of GCA and PMR. METHODS: Cross-sectional study with N = 100 patients with GCA and/or PMR (GCA-PMR). Patient-reported outcomes (PROs) were measured using the Short Form 36 Version 2 (SF-36v2) and visual analog scale (VAS) assessment. Moreover, the Patient Health Questionnaire 9 (PHQ-9) was used in 35 of 100 patients to detect depression. To compare PROs with physician assessment, VAS was also rated from physician perspective. To assess a possible association with inflammation itself, serological parameters of inflammation (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) were included. RESULTS: In all scales of the SF-36v2 except General Health (GH) and in the physical and mental sum score (PCS, MCS), a significant impairment compared to the German reference collective was evident (MCS: d = 0.533, p < 0.001). In the PHQ-9 categorization, 14 of the 35 (40%) showed evidence of major depression disorder. VAS Patient correlated significantly with PHQ-9 and SF-36 in all categories, while VAS Physician showed only correlations to physical categories and not in the mental dimensions. Regarding inflammatory parameters, linear regression showed CRP to be a complementary significant positive predictor of mental health subscale score, independent of pain. CONCLUSION: PRO show a relevant impairment of mental health up to symptoms of major depression disorder. The degree of depressive symptoms is also distinctly associated with the serological inflammatory marker CRP.
format Online
Article
Text
id pubmed-10262919
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102629192023-06-15 Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis Froehlich, Matthias Zahner, Antonia Schmalzing, Marc Gernert, Michael Strunz, Patrick-Pascal Hueper, Sebastian Portegys, Jan Schwaneck, Eva Christina Gadeholt, Ottar Kübler, Andrea Hewig, Johannes Ziebell, Philipp Front Med (Lausanne) Medicine OBJECTIVES: The spectrum of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) represents highly inflammatory rheumatic diseases. Patients mostly report severe physical impairment. Possible consequences for mental health have been scarcely studied. The aim of this study was to investigate psychological well-being in the context of GCA and PMR. METHODS: Cross-sectional study with N = 100 patients with GCA and/or PMR (GCA-PMR). Patient-reported outcomes (PROs) were measured using the Short Form 36 Version 2 (SF-36v2) and visual analog scale (VAS) assessment. Moreover, the Patient Health Questionnaire 9 (PHQ-9) was used in 35 of 100 patients to detect depression. To compare PROs with physician assessment, VAS was also rated from physician perspective. To assess a possible association with inflammation itself, serological parameters of inflammation (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) were included. RESULTS: In all scales of the SF-36v2 except General Health (GH) and in the physical and mental sum score (PCS, MCS), a significant impairment compared to the German reference collective was evident (MCS: d = 0.533, p < 0.001). In the PHQ-9 categorization, 14 of the 35 (40%) showed evidence of major depression disorder. VAS Patient correlated significantly with PHQ-9 and SF-36 in all categories, while VAS Physician showed only correlations to physical categories and not in the mental dimensions. Regarding inflammatory parameters, linear regression showed CRP to be a complementary significant positive predictor of mental health subscale score, independent of pain. CONCLUSION: PRO show a relevant impairment of mental health up to symptoms of major depression disorder. The degree of depressive symptoms is also distinctly associated with the serological inflammatory marker CRP. Frontiers Media S.A. 2023-05-12 /pmc/articles/PMC10262919/ /pubmed/37324155 http://dx.doi.org/10.3389/fmed.2023.1146815 Text en Copyright © 2023 Froehlich, Zahner, Schmalzing, Gernert, Strunz, Hueper, Portegys, Schwaneck, Gadeholt, Kübler, Hewig and Ziebell. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Froehlich, Matthias
Zahner, Antonia
Schmalzing, Marc
Gernert, Michael
Strunz, Patrick-Pascal
Hueper, Sebastian
Portegys, Jan
Schwaneck, Eva Christina
Gadeholt, Ottar
Kübler, Andrea
Hewig, Johannes
Ziebell, Philipp
Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
title Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
title_full Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
title_fullStr Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
title_full_unstemmed Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
title_short Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
title_sort patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262919/
https://www.ncbi.nlm.nih.gov/pubmed/37324155
http://dx.doi.org/10.3389/fmed.2023.1146815
work_keys_str_mv AT froehlichmatthias patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT zahnerantonia patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT schmalzingmarc patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT gernertmichael patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT strunzpatrickpascal patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT huepersebastian patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT portegysjan patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT schwaneckevachristina patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT gadeholtottar patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT kublerandrea patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT hewigjohannes patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis
AT ziebellphilipp patientreportedoutcomesprovideevidenceforincreaseddepressivesymptomsandincreasedmentalimpairmentingiantcellarteritis